Management EfficiencyThe company has return on total asset (ROA) of (11.81) % which means that it has lost $11.81 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (82.07) % meaning that it generated substantial loss on money invested by shareholders.
Entity SummaryOnxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 43 people.Onxeo SA (C4X) is traded on Frankfurt Stock Exchange in Germany. It is located in 49, Boulevard du g?n?ral Martial Valin and employs 43 people.
Onxeo SA Leadership Team
Stock Performance Indicators